Allogene Therapeutics officer Timothy Moore to depart Feb 28, 2025

Allogene Therapeutics, Inc.

Timothy Moore leaving employment on February 28, 2025; departure treated as termination without cause.
Eligible for cash severance and COBRA reimbursement under the company's Change in Control and Severance Benefit Plan, subject to release.
Company intends to enter into a consulting agreement with Moore, terms to be mutually agreed.
No immediate replacement for Moore has been announced.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Timothy Moore

Other Named Officer

ALLO · Allogene Therapeutics, Inc.

Effective: 2025-02-28
Filed: January 29, 2025, 6:59 PM ET

On January 23, 2025, Allogene Therapeutics, Inc. (the “Company”) and Timothy Moore agreed that Mr. Moore would be leaving his employment with the Company on February 28, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Timothy Moore departed as other_named_officer at Allogene Therapeutics, Inc..

Action: leaving employment

Exact text from the filing

On January 23, 2025, Allogene Therapeutics, Inc. (the “Company”) and Timothy Moore agreed that Mr. Moore would be leaving his employment with the Company on February 28, 2025.

View on SEC.gov

Allogene Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-014985

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.